INTRODUCTION
There are currently nine recombinant human growth hormone (rhGH) products available in the USA for ten different indications [1] . Most of these rhGH products are approved for one or more indications. Growth hormone deficiency (GHD), idiopathic short stature (ISS), and Turner syndrome (TS) are some of the indications for which an rhGH is prescribed.
Patients with GHD or ISS make up the majority of the pediatric population receiving growth hormone treatment [1] . GHD affects *1 in 3,500 children [2] . In 2003, the Food and Drug Administration approved rhGH for children with ISS whose height is more than 2.25 standard deviations (SD) below the mean (or below the 1st percentile). Since the specific etiology for ISS in children is sometimes difficult to identify, children are often diagnosed with ISS and receive growth hormone (GH) therapy [3, 4] . TS occurs *1 in 2,000-2,300 live female births [5] .
Omnitrope Ò (Sandoz) is one of the rhGH products available in the USA. It was developed as a medicinal product similar to the reference rhGH product, Genotropin Ò (Pfizer Inc.). Longterm studies comparing Omnitrope and
Genotropin have shown similar efficacy and safety [6] [7] [8] [9] . Physicians are often confronted with the need to change the rhGH used by their patients due to health plan and/or patients' insurance demands. Tanner et al. [15] . Standardization of HV was based on the table provided by Tanner et al. [15] . We required three visits pre-and postswitch; when visits did not fall into the exact time position, we interpolated the data; we used the closest before and after height measurements to the time position of need and calculated the height point.
Statistical Analysis
Descriptive statistical analysis was performed using SAS Version 9.2 (SAS Institute Inc., Cary, NC, USA). Continuous parameters were summarized using descriptive statistics including mean and SD. Categorical parameters were summarized using frequencies and percentages. We conducted a quasiexperimental analysis in which the subjects were evaluated pre-and post-switch to Omnitrope therapy.
RESULTS

Patient Characteristics
A total of 103 patients were included in the study: 57 patients with GHD, 26 with ISS, and 20 with TS. Patient baseline clinical characteristics are summarized in Table 1 .
There were slightly more pre-pubertal patients than pubertal patients among the GHD and TS patients, whereas the opposite occurred among the ISS patients. Similarly, the pre-pubertal patients were younger among the GHD and TS groups than in the ISS children. The youngest patient was 4-year old with TS. The mean total dose of rhGH given to the patients was similar among the three groups of patients during the pre-pubertal and pubertal stages. The mean duration patients were on a non-Omnitrope rhGH therapy was 4.6 years (SD ±1.24 years, minimum 1.52 years, maximum 5.84 years).
Height
The mean overall height at index date was 137.76 ± 18.72 cm for all patients, and the mean height at 15 months post-switch for all the patients was 144.28 ± 18.52 cm, showing an increase of 6.52 cm ( Table 2) 
Height SDS
The mean HSDS for all subjects at index date was -1.49 ± 1.01; HSDS increased by an average of 0.04 over the 15-month post-switch period (Table 2) . Within each category, the subjects' mean HSDS at the index date was -1.23 ± 1.06, -1.70 ± 0.80, and -1.97 ± 0.90 for the patients diagnosed with GHD, ISS, and TS, respectively.
Those with GHD improved, on average, by 0.07; those with ISS improved, on average, by 0.13; patients with TS had a change of -0.15 (Table 3 ). 13.56 ± 14.00 ± 
Height Velocity
The mean HV for all patients at index date was 6.00 ± 1.93 cm/year. Over the 15-month postswitch period, mean HV decreased by 1.06 cm/ year ( (Table 3) .
Height Velocity SDS
The mean HVSDS for all patients was 0.78 ± 2.90 over the 15-month post-switch period. During the initial 6 months, there was an increase for all patients in HVSDS (at 3 months HVSDS was 1.03 ± 2.86, at 6 months HVSDS was 1.16 ± 3.20); however, after 9 months the HVSDS for all patients declined slightly ( Table 2 ; Fig. 4 ). This could be contributed to the advancing age. The patients mean HVSDS declined by an average of 0.52 over the 15-month post-switch period (Table 2 ; 
DISCUSSION
This present study has used real-world retrospective data to evaluate the impact of Table 1 continued HSDS Height standard deviation score, HV height velocity, HVSDS height velocity standard deviation score a HV and HVSDS demonstrate the expected decline associated with advancing age negatively impacting the growth trajectories of the treated patients. This applies to the overall study population and also when considering the indication-specific subgroups (GHD, TS, ISS).
Patients were on a non-Omnitrope rhGH therapy for a mean duration of 4.6 years (SD ±1.24 years, minimum 1.52 years, maximum 5.84 years) and it has been shown in previous studies [16] [17] [18] [19] [20] that administration of growth hormone to children with GHD or ISS results in marked acceleration in linear growth, mostly during the first years of treatment. After 4-10 years of treatment, the HSDS increase a HV and HVSDS demonstrate the expected decline associated with advancing age GHD Growth hormone deficiency, HSDS height standard deviation score, HV height velocity, HVSDS height velocity standard deviation score, ISS idiopathic short stature, TS Turner syndrome wanes and does not differ significantly from the predicted score in the absence of therapy [16] [17] [18] [19] [20] . In this study, patients continued to grow in height and HSDS in all categories from index to 15 months post-switch. Results are expected and understandable given the age, overall duration of GH treatment, and pubertal status of the study population [16] [17] [18] [19] [20] . The mean HV for all patients in the study was 6.00 ± 1.93 cm/ year over the 15-month post-switch period and is consistent with other reports of patients at similar durations of treatment [16, 17] . We recognize that the GH therapy dose that was used in TS patients pre-and post-switch was less than the recommended dose of 0.375 mg/kg/ week. Nonetheless, patients' individual height profiles were maintained after the switch. The overall growth rate for all the patients was similar with the similar GH dosages, and this may be due to how we identified the diagnosis codes for each patient in GH therapy. However, we reviewed the chart for each patient and tried Physicians are often faced with the need to change rhGH therapy, due to health plan and/ or changes to a patient's insurance, and this may be a cause of concern. Previous studies that have examined the impact of switching rhGH products have focused on parameters such as physician attitudes or the administrative burden on clinics, with the suggestion that patient care may be negatively impacted [21] . Alternatively, a comparative analysis of data from phase 3 studies demonstrated that switching rhGH therapy (from Genotropin to Omnitrope) has no impact on efficacy or safety in children with GHD [22] . More recently, a study from Sweden showed that patients with a range of pediatric growth disturbances could be successfully switched from Genotropin to Omnitrope, with no negative impact on growth and no serious or unexpected adverse drug reactions [23] .
A limitation of our study is the retrospective nature of the analyses. Nevertheless, reporting of real-world data is of great value. We cannot exclude the possibility of inaccurate entry of data in the eMR system, although this possibility is equally likely to have occurred pre-and post-switch. We also required three visits that were 3 months apart during pre-and post-switch; however, some visits did not fall into the exact time position. We interpolated the data for some of these time positions using the closest height measurements before and after the time position of need, and calculated the height point.
CONCLUSION
This study used real-world retrospective data to examine the impact of switching from a nonOmnitrope rhGH to Omnitrope. The study demonstrated that patients continued to grow without alteration in their growth trajectories and can therefore be switched from a nonOmnitrope rhGH to Omnitrope without any negative impact on their growth. Our findings should be a useful resource for physicians who are faced with the possibility of switching rhGH therapy. 
